Aignostics is an international, interdisciplinary team powering the next generation of precision medicine and advancing AI and pathology. Established as a spin-off from Charité Berlin in 2020, the company builds on extensive research and expertise from Charité, TU Berlin, and Fraunhofer HHI.

With offices in Berlin and New York, Aignostics offers a suite of rigorously developed products and custom services aimed at transforming drug development and improving patient outcomes through novel AI-driven insights.

Our mission is to revolutionize precision medicine by leveraging AI to deliver novel and actionable insights, enabling better drug development and patient care.

Our team includes data scientists, machine learning engineers, pathologists, and biologists who provide expert oversight across our products and services.

Aignostics holds certifications such as ISO 13485 and 27001 and features a GCP-ready clinical trial platform, underscoring our commitment to quality and clinical readiness.

Led by co-founders Viktor Matyas (CEO) and Maximilian Alber (CTO), among others, our leadership team brings deep expertise and a global perspective.

We foster a culture of fairness, honesty, humility, and teamwork, driven by core values including mission ownership, idea meritocracy, and sustainabile high performance.

Aignostics is a mission-driven startup eager to expand its diverse and growing team. We offer meaningful opportunities for those passionate about applying AI in medicine and making a positive impact on healthcare.

We invite talent to explore current openings on our careers page.